CO-DIAGNOSTICS, INC. Form 8-K (May 14, 2020)

Summary

Current report on Form 8-K of Co-Diagnostics, Inc. reporting an event dated May 14, 2020. Under Item 2.02 the company states that it issued a press release reporting its financial results for the three months ended March 31, 2020, attached as Exhibit 99.1. It states that a conference call took place the same day and that the telephone bridge was not sufficient to allow the call to take place, so a transcript is attached as Exhibit 99.2. The signature block carries /s/ Dwight H. Egan, Chief Executive Officer, dated May 15, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

FORM
8-K

CURRENT
REPORT

Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date
of report (Date of earliest event reported): May 14, 2020

CO-DIAGNOSTICS,
 INC.
(Exact
 name of small business issuer as specified in its charter)
Utah | 1-38148 | 46-2609363
(State
 or other jurisdiction of
 incorporation or organization) | (Commission File
 Number) | (IRS
 Employer Identification
 Number)

2401
S. Foothill Drive, Suite D, Salt Lake City, Utah 84109

(Address
of principal executive offices)

(801)
438-1036

(Issuer’s
telephone number)

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

[ ] | Written
 communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] | Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] | Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] | Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Securities
registered pursuant to Section 12(b) of the Act:

Title
 of each class | Trading
 Symbol(s) | Name
 of exchange on which registered
Common
 Stock, par value $0.001 per share | CODX | NASDAQ
 Capital Market

Emerging
growth company [X]

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Item 2.02. Results of Operations and Financial Condition.

On
May 14, 2020, Co-Diagnostics, Inc. (the “Company”) issued a press release reporting the financial results of the Company
for the three months ended March 31, 2020. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated
herein by this reference.

Also,
on May 14, 2020, the Company held a conference call. A transcript of the call is attached as Exhibit 99.2 to this Current Report
on Form 8-K.

Item 7.01. Regulation FD Disclosure.

As
noted above, the Company held a conference call on May 14, 2020, to discuss the Company’s operating results for the three
months ended March 31, 2020. The telephone bridge was not sufficient to allow the call to take place and a transcript of the call
is attached as Exhibit 99.2 to this Current Report on Form 8-K.

A
copy of the press release, which contains additional information regarding how to access the conference call and how to listen
to a recorded playback of the call, is attached as Exhibit 99.1 to this Current Report on Form 8-K. A transcript of the call is
attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

*
* * *

The
information discussed under Item 2.02 and Item 7.01 above, including Exhibit 99.1 and Exhibit 99.2 shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing by the
Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d)
Exhibits.

99.1 | Press release of Co-Diagnostics, Inc., dated May 14, 2020.
99.2 | Transcript of conference call of Co-Diagnostics, Inc., dated May 14, 2020.

SIGNATURE

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, hereunto duly authorized.

CO-DIAGNOSTICS,
 INC.
By: | /s/
 Dwight H. Egan
Name: | Dwight
 H. Egan
Title: | Chief
 Executive Officer

Date:
May 15, 2020

File and source

File

SEC_CODX_8-K_filed2020-05-15_0001493152-20-008931.htm

Size

32,100 bytes

SHA-256

7a5c83c4e341ee920d1fffb394fc76c198217733554b61bf0b2315192c66f305

Our copy

SEC_CODX_8-K_filed2020-05-15_0001493152-20-008931.htm

Original

www.sec.gov